THE NICKLES GROUP, LLC for AMGEN
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Monitored implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act and issues regarding drug pricing. H.R. 3517 / S. 1943, Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021. Issues regarding ESRD payments.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRETT BAKER | — |
| GREG D'ANGELO | — |
| MARY BETH SAVARY TAYLOR | — |
Health Issues HCR
S. 4348, FDASLA Act of 2022 and H.R. 7667, Food and Drug Amendments of 2022. Issues regarding timely access to medications. H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023 and issues related to the FDA.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRETT BAKER | — |
| GREG D'ANGELO | — |
| MARY BETH SAVARY TAYLOR | — |
Copyright/Patent/Trademark CPT
S. 2774, Pride in Patent Ownership Act. S. 4430, Interagency Patent Coordination and Improvement Act of 2022. H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023 and issues concerning FTC filing fees.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFF CHOUDHRY | — |
| GREG D'ANGELO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.